Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Ptc Therapeutics (PTCT)

Ptc Therapeutics (PTCT)
40.98 -1.77 (-4.14%) 14:00 ET [NASDAQ]
40.82 x 503 41.14 x 106
Realtime by (Cboe BZX)
40.82 x 503 41.14 x 106
Realtime 41.00 -1.75 (-4.09%) 09:30 ET
Quote Overview for Thu, Apr 10th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
38.70
Day High
41.00
Open 41.00
Previous Close 42.75 42.75
Volume 344,459 344,459
Avg Vol 1,084,047 1,084,047
Stochastic %K 13.66% 13.66%
Weighted Alpha +27.51 +27.51
5-Day Change -7.36 (-15.75%) -7.36 (-15.75%)
52-Week Range 24.00 - 58.38 24.00 - 58.38
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,371,650
  • Shares Outstanding, K 78,869
  • Annual Sales, $ 806,780 K
  • Annual Income, $ -363,300 K
  • EBIT $ -82 M
  • EBITDA $ 142 M
  • 60-Month Beta 0.58
  • Price/Sales 3.89
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 82.25% ( -8.80%)
  • Historical Volatility 66.59%
  • IV Percentile 97%
  • IV Rank 80.33%
  • IV High 91.26% on 12/17/24
  • IV Low 45.45% on 01/23/25
  • Put/Call Vol Ratio 0.00
  • Today's Volume 29
  • Volume Avg (30-Day) 150
  • Put/Call OI Ratio 0.86
  • Today's Open Interest 5,323
  • Open Int (30-Day) 5,168

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.84
  • Number of Estimates 7
  • High Estimate 12.10
  • Low Estimate -1.53
  • Prior Year -1.20
  • Growth Rate Est. (year over year) +170.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.32 +5.49%
on 04/09/25
Period Open: 52.49
58.38 -32.56%
on 03/17/25
-13.12 (-25.00%)
since 03/10/25
3-Month
37.32 +5.49%
on 04/09/25
Period Open: 43.94
58.38 -32.56%
on 03/17/25
-4.57 (-10.40%)
since 01/10/25
52-Week
24.00 +64.08%
on 04/25/24
Period Open: 26.91
58.38 -32.56%
on 03/17/25
+12.46 (+46.30%)
since 04/10/24

Most Recent Stories

More News
PTC Therapeutics: Q4 Earnings Snapshot

PTC Therapeutics: Q4 Earnings Snapshot

PTCT : 40.88 (-4.37%)
PTC Therapeutics Stock Eyes Further Rally After Price-Target Hikes On Huntington’s Therapy Deal With Novartis: Retail Buzz Grows

Wells Fargo highlighted the agreement’s $1.9 billion milestone potential, 40% U.S. profit-sharing terms, and double-digit royalties on ex-U.S. sales.

PTCT : 40.88 (-4.37%)
NVS : 102.41 (-1.39%)
PTC Therapeutics: Q3 Earnings Snapshot

PTC Therapeutics: Q3 Earnings Snapshot

PTCT : 40.88 (-4.37%)
3 Top Stocks That Could Still Rocket Higher in 2024

Upcoming Food and Drug Administration decisions could push these stocks through the roof.

PTCT : 40.88 (-4.37%)
VRTX : 472.99 (-1.93%)
BBIO : 32.16 (-2.19%)
RHHBY : 36.4500 (-1.75%)
PFE : 21.56 (-4.14%)
PTC Therapeutics: Q2 Earnings Snapshot

PTC Therapeutics: Q2 Earnings Snapshot

PTCT : 40.88 (-4.37%)
Nike, Kura Sushi fall; Infinera, Protagonist Therapeutics rise, Friday, 6/28/2024

Stocks that traded heavily or had substantial price changes on Friday: Nike, Kura Sushi fall; Infinera, Protagonist Therapeutics rise

FCX : 31.54 (-6.52%)
PTCT : 40.88 (-4.37%)
ACCD : 7.02 (-0.14%)
KRUS : 51.30 (-5.99%)
PTGX : 41.92 (-1.53%)
INFN : 6.64 (-0.15%)
PTC Therapeutics: Q1 Earnings Snapshot

PTC Therapeutics: Q1 Earnings Snapshot

PTCT : 40.88 (-4.37%)
PTC Therapeutics: Q4 Earnings Snapshot

PTC Therapeutics: Q4 Earnings Snapshot

PTCT : 40.88 (-4.37%)
1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?

Bad news for one player does not always equal good news for another.

SRPT : 52.80 (-5.12%)
PTCT : 40.88 (-4.37%)
PTC Therapeutics: Q3 Earnings Snapshot

PTC Therapeutics: Q3 Earnings Snapshot

PTCT : 40.88 (-4.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.

See More

Key Turning Points

3rd Resistance Point 52.19
2nd Resistance Point 48.13
1st Resistance Point 45.44
Last Price 40.88
1st Support Level 38.69
2nd Support Level 34.63
3rd Support Level 31.94

See More

52-Week High 58.38
Fibonacci 61.8% 45.24
Fibonacci 50% 41.19
Last Price 40.88
Fibonacci 38.2% 37.13
52-Week Low 24.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar